Immunicum
Immunicum (operating as Mendus) is a clinical-phase II Swedish biotechnology company developing immune-based cancer therapies, with lead candidate Vididencel in high-risk ovarian cancer and the VITAL-CML trial in chronic myeloid leukemia.
- Company typePublic
- Founded2002
- HeadquartersGothenburg, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Immunicum does
Immunicum, now operating under the trade name Mendus, is a clinical-stage biotechnology company headquartered in Stockholm, Sweden, with R&D operations in Leiden, the Netherlands. The company develops immune-based cancer therapies designed to reduce tumor recurrence by harnessing the immune system to target residual cancer cells that may remain after initial cancer treatment. Its primary patient population consists of cancer patients at risk of tumor recurrence following initial therapy, a clinical problem the company identifies as the leading cause of cancer-related mortality.
The company's pipeline centers on Vididencel, an immune-based therapy candidate being investigated for high-risk ovarian cancer and designed to activate broad immune responses against cancer cells. A second program, the VITAL-CML trial, targets chronic myeloid leukemia, with the first patient enrolled in 2026. The platform approach relies on dendritic cell-based immunotherapy to provoke systemic immune surveillance against residual disease. Mendus is publicly listed on NASDAQ Stockholm under the ticker IMMU and was originally founded in 2002.
As a clinical-phase II biotech with no commercialized products, Immunicum/Mendus generates no product revenue and does not disclose pricing. Operations have been funded through equity capital markets, with disclosed funding rounds totaling approximately $54.6 million ($15.5M in 2015 and $39.1M in 2018). The company employs between 11 and 50 staff and communicates with stakeholders primarily through investor relations, a LinkedIn corporate page, and participation in industry conferences. Go-to-market mechanics will be determined upon regulatory approval and commercial market entry.
Immunicum firmographics
Firmographics- Name
- Immunicum
- Legal name
- Mendus AB (publ)
- Website
- https://immunicum.se
- Company type
- Public
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Immunicum (operating as Mendus) is a clinical-phase II Swedish biotechnology company developing immune-based cancer therapies, with lead candidate Vididencel in high-risk ovarian cancer and the VITAL-CML trial in chronic myeloid leukemia.
- Ownership category
- akta.pro rank
Immunicum industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Dendritic Cell & Other APC-based Therapies (HLAAABAF)
- akta.pro secondary industries
- Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
Keywords
Where Immunicum is headquartered
LocationHeadquarters
- HQ city
- Gothenburg
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
Immunicum business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Marketing channels1 record
Immunicum product offering
Product offeringCore offering
Immunicum is a clinical-phase biopharmaceutical company developing immune-based cancer therapies intended to reduce tumor recurrence by targeting residual cancer cells that remain after initial treatment. Its lead candidate Vididencel is being investigated in high-risk ovarian cancer, and the company is also advancing the VITAL-CML trial for chronic myeloid leukemia. The company does not yet have any commercialized products on the market.
Product overview
Mendus is developing a pipeline of immune-based cancer therapies focused on reducing tumor recurrence by harnessing the immune system to act against residual cancer cells. The company's approach centers on improving long-term survival of cancer patients while preserving health and quality of life. Key programs include Vididencel, which is being studied in high-risk ovarian cancer, and the VITAL-CML trial for chronic myeloid leukemia. The company is listed on NASDAQ Stockholm under ticker IMMU.
Differentiator
Problem solved
Functional benefit
Products and services
- Vididencel Vididencel is an immune-based therapy candidate designed to activate broad immune responses against cancer cells; it is being investigated for the treatment of high-risk ovarian cancer with the goal of reducing tumor recurrence.
- Cancer Immunotherapy Pipeline A pipeline of immune-based therapies developed by the company, focused on reducing tumor recurrence by harnessing the immune system to target residual cancer cells across multiple oncology indications, including the VITAL-CML trial for chronic myeloid leukemia.
Companies that use Immunicum
Customer profileSegments1 record
Ideal customer profiles1 record
Immunicum technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Immunicum partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Immunicum competitors and assessment
Company assessmentDirect peers
- Northwest Biotherapeutics: Northwest Biotherapeutics develops dendritic cell-based cancer immunotherapies (DCVax), making it one of the closest direct competitors to Mendus's Vididencel program in the autologous cell therapy oncology space.
- Immatics: Immatics develops TCR-based immunotherapies and adoptive cell therapies for cancer, making it a directly comparable European-listed immuno-oncology peer to Mendus with a similar mission of targeting solid tumors.
- Allogene Therapeutics: Allogene is a clinical-stage cell therapy company developing allogeneic CAR T-cell therapies for cancer, operating in the same cell therapy oncology category as Mendus and competing for similar investor and partnership capital.
- Atara Biotherapeutics: Atara develops allogeneic T-cell and CAR T immunotherapies for solid tumors and hematologic cancers, positioning it as a directly comparable clinical-stage cell therapy peer to Mendus with overlapping oncology indications.
- Iovance Biotherapeutics: Iovance is a leading cell therapy company focused on tumor-infiltrating lymphocyte (TIL) therapies for solid tumors, directly competing with Mendus in the cell-based cancer immunotherapy category with a more advanced commercial-stage product (Amtagvi).
- Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors, placing it in the same cell therapy oncology category as Mendus with overlapping target indications in solid tumor recurrence.
Broad incumbents
- Bristol Myers Squibb: BMS's Opdivo (nivolumab) and Yervoy (ipilimumab) form a broad incumbent immuno-oncology franchise that competes with cell therapy approaches across the same indications Mendus is pursuing.
- Merck & Co. Merck's Keytruda (pembrolizumab) dominates the immuno-oncology checkpoint inhibitor market and represents a broad incumbent competitive threat to cell therapy approaches like Mendus's Vididencel across multiple oncology indications.
- BioNTech: BioNTech is a larger German immuno-oncology company with a broad portfolio of mRNA-based cancer immunotherapies and cell therapies, representing a broad incumbent competitor to Mendus in the cancer immunotherapy space.
Emerging players
- CoImmune (formerly GENICA): CoImmune is a clinical-stage biotechnology company developing cell-based immunotherapies for solid tumors, making it an emerging player with partial overlap to Mendus's dendritic cell and immune-based oncology approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Immunicum social profiles
Digital presenceImmunicum financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immunicum leadership team
Management profileNumber of profiles
Profiles5 records
Immunicum funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immunicum M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immunicum
What does Immunicum do?
Immunicum is a clinical-phase biopharmaceutical company developing immune-based cancer therapies intended to reduce tumor recurrence by targeting residual cancer cells that remain after initial treatment. Its lead candidate Vididencel is being investigated in high-risk ovarian cancer, and the company is also advancing the VITAL-CML trial for chronic myeloid leukemia. The company does not yet have any commercialized products on the market.
Is Immunicum a public or private company?
Immunicum is a public company. It is classified as public and is currently operating.
When was Immunicum founded?
Immunicum was founded in 2002. It employs 11 to 50 people.
Where is Immunicum based?
Immunicum is headquartered in Gothenburg, Sweden, in the Europe region.
Who are Immunicum's main competitors?
Direct peers on record are Northwest Biotherapeutics, Immatics, Allogene Therapeutics, Atara Biotherapeutics, Iovance Biotherapeutics and Adaptimmune Therapeutics. Broad incumbents are Bristol Myers Squibb, Merck & Co. and BioNTech. CoImmune (formerly GENICA) is listed as an emerging player.
Does Immunicum have an API?
No public API is recorded for Immunicum.
What industry is Immunicum in?
Immunicum's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAF, Dendritic Cell & Other APC-based Therapies, with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 325414 and its SIC code is 2836.